Pemphigus. S2 Guideline for Diagnosis and Treatment--guided by the European Dermatology Forum (EDF) in Cooperation with the European Academy of Dermatology and Venereology (EADV)

Overview

Journal J Eur Acad Dermatol Venereol

Specialty Infectious Diseases

Date 2014 Oct 24

PMID 25338479

Citations 78

Authors

M Hertl

H Jedlickova

S Karpati

B Marinovic

S Uzun

S Yayli

D Mimouni

L Borradori

C Feliciani

D Ioannides

P Joly

C Kowalewski

G Zambruno

D Zillikens

M F Jonkman

Affiliations

Soon will be listed here.

Abstract

Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available.

Objectives: For this reason, a group of European dermatologists with a long-standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus.

Results: This group identified the statements of major agreement or disagreement regarding the diagnostic and therapeutic management of pemphigus. The revised final version of the pemphigus guideline was finally passed on to the European Dermatology Forum (EDF) for a final consensus with the European Academy of Dermatology and Venereology (EADV) and the European Union of Medical Specialists (UEMS).

Citing Articles

Exploring the role of glucocorticoid receptors and co-chaperones in Pemphigus foliaceus stratification.

Tahri S, Fakhfakh R, Bahloul E, Charfi S, Sellami K, Hachicha H Arch Dermatol Res. 2025; 317(1):479.

PMID: 39988616 DOI: 10.1007/s00403-025-03864-1.

Case report: A rollercoaster journey of pemphigus vegetans.

Hou X, Chen J Front Immunol. 2025; 15:1481192.

PMID: 39872528 PMC: 11769805. DOI: 10.3389/fimmu.2024.1481192.

Unbiased screening identifies regulators of cell-cell adhesion and treatment options in pemphigus.

Franz H, Rathod M, Zimmermann A, Studle C, Beyersdorfer V, Leal-Fischer K Nat Commun. 2024; 15(1):8044.

PMID: 39271654 PMC: 11399147. DOI: 10.1038/s41467-024-51747-2.

A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus.

Balaceanu-Gurau B, Dumitrascu A, Giurcaneanu C, Tatar R, Gurau C, Orzan O Vaccines (Basel). 2024; 12(8).

PMID: 39203983 PMC: 11360219. DOI: 10.3390/vaccines12080857.

Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.

Manzari Tavakoli G, Yazdanpanah N, Rezaei N Adv Rheumatol. 2024; 64(1):61.

PMID: 39169436 DOI: 10.1186/s42358-024-00401-y.